scholarly journals Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response

Gut ◽  
2004 ◽  
Vol 53 (1) ◽  
pp. 91-98 ◽  
Author(s):  
E Furrie
2013 ◽  
Vol 144 (5) ◽  
pp. S-832 ◽  
Author(s):  
Rodrigo Quera ◽  
Marjorie De La Fuente ◽  
David Díaz-Jiménez ◽  
Roberto Vidal ◽  
Francisco López-Kostner ◽  
...  

2008 ◽  
Vol 134 (4) ◽  
pp. A-510
Author(s):  
Laura Stronati ◽  
Anna Negroni ◽  
Maria Pierdomenico ◽  
Ilaria Menghi ◽  
Giulia Maiella ◽  
...  

2008 ◽  
Vol 40 ◽  
pp. S43
Author(s):  
L. Stronati ◽  
S. Cucchiara ◽  
A. Negroni ◽  
M. Pierdomenico ◽  
V. Labalestra ◽  
...  

2007 ◽  
Vol 179 (1) ◽  
pp. 295-304 ◽  
Author(s):  
Uta Berndt ◽  
Sebastian Bartsch ◽  
Lars Philipsen ◽  
Silvio Danese ◽  
Bertram Wiedenmann ◽  
...  

2019 ◽  
Vol 26 (3) ◽  
pp. e14-e15
Author(s):  
Celia Escudero-Hernández ◽  
Enrique Montalvillo ◽  
Beatriz Antolín ◽  
David Bernardo ◽  
José Antonio Garrote ◽  
...  

Intraepithelial immune response can be studied by flow cytometry. The proportion of CD3+ cells differs between Crohn’s disease and ulcerative colitis.


2006 ◽  
Vol 247 ◽  
pp. 1-4

In a nutshellInflammatory bowel diseases can involve problems in the development of the gut's immune response. A healthy bowel flora plays an important role in this development, for example through effects on cytokines.Clinical trials of probiotics for IBD have been predominantly positive for ulcerative colitis and pouchitis, less so for Crohn's disease. So far probiotics appear to be a notably safe therapy, although some theoretical safety issues need to be borne in mind.


Sign in / Sign up

Export Citation Format

Share Document